The first stop for professional medicines advice

Biosimilars

25 results

Applied filters

Good governance when implementing ranibizumab biosimilar

29 June 2022Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance

The licence and supporting evidence for ranibizumab biosimilars

29 June 2022Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence

Implementing ustekinumab biosimilar

4 September 2024This webinar provided information and guidance to support organisations switch to the best value ustekinumab biosimilar

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

Preparing to use ustekinumab biosimilar

16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.

Guidance Handling of Monoclonal Antibody (mAb) and Products (Yellow Cover)

16 December 2016Variation in practice underlined the need for an evidence-based guideline for handling mAbs that was suited to all those providing care to NHS patients.

Understanding biological and biosimilar medicines

29 June 2022Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions

The licence and supporting evidence for natalizumab biosimilar

6 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.

The licence and supporting evidence for tocilizumab biosimilar

5 March 2024One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.
admin